Back to all Laboratorio Reig Jofre S.A. press releases
Laboratorio Reig Jofre S.A.
- BME:RJF
REIG JOFRE reports €331.1M revenue for 2025 as Toledo upgrades weigh on antibiotics
Published
At a glance
- Company
- Laboratorio Reig Jofre S.A.
- Listings
- BME:RJF
- Announcement type
- Financial results
- Published
- Reporting period
- 2025 full year
- Source announcement
- reigjofre.com
| Measure | Figure | Period | Compared with |
|---|---|---|---|
| Revenue | €331.1M | 2025 | -2% vs 2024 |
| Antibiotics (Toledo) | 30% decline | 2025 | 30% decline vs 2024 |
| Gross margin | 59% | 2025 | slightly above 2024 vs 2024 |
| Reported EBITDA | €30.5M | 2025 | Not stated |
| Consolidated net income | €5.0M | 2025 | Not stated |
| Net debt | €101.1M | 2025 | Not stated |
Figures are quoted from this announcement and selected automatically.
FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices
Announcement Summary
REIG JOFRE (BME:RJF) published its 2025 full-year financial results.
- Revenue was €331.1M, a decrease of 2% compared with 2024.
- Antibiotics represented 20% of 2024 sales and declined 30% in 2025 after Toledo capacity was reduced.
- Gross margin was 59%; reported EBITDA was €30.5M, with a 9.2% margin.
- Consolidated net income was €5.0M amid a change in consolidation scope and related accounting impacts.
- Net debt was €101.1M; net debt/EBITDA was 3.3x, or 2.5x excluding Leanbio and Syna Therapeutics.
The Toledo reduction followed upgrades to two production lines to meet new GMP requirements. REIG JOFRE also reported participation in EMINTECH and vertical integration with Leanbio. REIG JOFRE said it continues its modernization plan to restore capacity, efficiency, and commercial momentum beginning in 2026.
Investor FAQs
Source announcement
- Company
- Laboratorio Reig Jofre S.A.
- Title
- REIG JOFRE publishes its 2025 full year financial results
- Published
- Source site
- reigjofre.com
Read the source announcement on reigjofre.com
FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.
Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.
Read the original press release
Full text as published, unedited.